Venrock Healthcare Capital Partners II L.P. 13D and 13G filings for Cogent Biosciences, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-11 6:28 pm Sale |
2024-09-30 | 13G | Cogent Biosciences, Inc. COGT |
Venrock Healthcare Capital Partners II L.P. | 6,446,917 5.800% |
-5,069,750 (-44.02%) |
Filing |
| 2024-11-14 5:47 pm Purchase |
2024-09-30 | 13G | Cogent Biosciences, Inc. COGT |
Venrock Healthcare Capital Partners II L.P. | 11,516,667 9.990% |
2,477,823 (+27.41%) |
Filing |
| 2024-02-14 8:33 pm Purchase |
2023-12-31 | 13G | Cogent Biosciences, Inc. COGT |
Venrock Healthcare Capital Partners II L.P. | 9,038,844 9.990% |
1,729,716 (+23.67%) |
Filing |
| 2023-02-14 4:55 pm Purchase |
2022-12-31 | 13G | Cogent Biosciences, Inc. COGT |
Venrock Healthcare Capital Partners II L.P. | 7,309,128 9.990% |
3,007,002 (+69.90%) |
Filing |
| 2022-02-14 4:14 pm Purchase |
2021-12-31 | 13G | Cogent Biosciences, Inc. COGT |
Venrock Healthcare Capital Partners II L.P. | 4,302,126 9.990% |
4,302,126 (New Position) |
Filing |